The Study
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus
This study compared two types of insulin in 18 people with diabetes and found that one (Gla-300) made their bodies produce less fat-burning chemicals and less glucagon. But it didn't test if this made people feel better or have fewer low blood sugar episodes — just what happened in a lab setting for 24 hours.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
This study tested two types of long-acting insulin in people with type 1 diabetes to see which one better stops the body from making too many ketones.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 554 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Lower ketones mean less risk of dangerous diabetic ketoacidosis, even if blood sugar stays the same — so Gla-300 may offer extra protection.
- 2Gla-300 lowered fat breakdown (free fatty acids) by 19%, glycerol by 22%, and ketones (β-hydroxybutyrate) by 28% compared to Gla-100, without changing blood sugar levels.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes Technology & Therapeutics
Year
2020
Authors
P. Lucidi, F. Porcellati, Patrizia Cioli, Paola Candeloro, A. Marinelli Andreoli, G. Bolli, C. Fanelli
Related Content
Claims (6)
In adults with type 1 diabetes, a higher concentration of insulin glargine U300 reduces glucagon levels more than a lower concentration of insulin glargine U100 over 24 hours, leading to a higher insulin-to-glucagon ratio that lowers liver glucose output and ketone production without changing overall blood sugar levels.
In adults with type 1 diabetes, insulin glargine U300 lowers blood levels of β-hydroxybutyrate by about 28% compared to insulin glargine U100 when blood glucose is held at normal levels.
In adults with type 1 diabetes, insulin glargine U300 provides a steadier level of insulin over 24 hours, with lower peaks in the first 12 hours and higher levels in the second 12 hours than insulin glargine U100, while delivering the same total amount of insulin over the full day.
In adults with type 1 diabetes, insulin glargine U300 lowers free fatty acid and glycerol levels in the blood more than insulin glargine U100 when blood glucose is held steady.
In adults with type 1 diabetes, two forms of insulin—glargine U300 and glargine U100—result in the same total glucose metabolism over 24 hours, even though they affect glucagon, fat breakdown, and ketone production differently.
High insulin levels reduce the breakdown of fat by decreasing the activity of hormone-sensitive lipase.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.